In the recently concluded American Association of Cancer Research (AACR) meeting, held in San Diego, US, from 5-10 Apr 2024, Arbele presented data from 4 discovery/preclinical programs and 1 diagnostics program in poster presentations.

These represent the important studies in different therapeutic modalities in the GI cancers space, demonstrating our continuous innovation at Arbele. We are proud of our significant progress made over the last years and are excited to have the opportunity to share our data. We look forward to further push these programs into preclinical and clinical validations.

💡Abstract: 3131
Novel CDH17-targeting antibody-drug conjugate exhibits anti-tumor efficacy in preclinical models of gastrointestinal cancers
https://aacrjournals.org/cancerres/article/84/6_Supplement/3131/735457/Abstract-3131-Novel-CDH17-targeting-antibody-drug

💡Abstract:3212
Development of a Trop2/CD3 bispecific antibody with modulated Trop2 bindingaffinity as a novel immunotherapy for advanced gastrointestinal cancertreatment
https://aacrjournals.org/cancerres/article/84/6_Supplement/3212/735977/Abstract-3212-Development-of-a-Trop2-CD3

💡Abstract:3213
A novel CDH17/PD-1 bispecific antibody for treatment of advancedgastrointestinal cancers
https://aacrjournals.org/cancerres/article/84/6_Supplement/3213/735976/Abstract-3213-A-novel-CDH17-PD-1-bispecific

💡Abstract:1326
Pre-clinical development of ARB011: A CDH17 targeting allogeneic nonviralRNA-based “Flash” CAR-NK therapy for gastrointestinal cancer
https://aacrjournals.org/cancerres/article/84/6_Supplement/1326/737798/Abstract-1326-Pre-clinical-development-of-ARB011-A?searchresult=1

💡Abstract:1061
Diagnostic application of a novel blood CDH17 immunoassay in the detection ofcolorectal adenoma
https://aacrjournals.org/cancerres/article/84/6_Supplement/1061/737459/Abstract-1061-Diagnostic-application-of-a-novel

‍